XPO1 and neoplasm: Reports exploring the relationship between SINE efficacy and tumor models with E571K XPO1 have been discussed previously, suggesting a slight reduction in SINE efficacy in PMBCL cell lines (MedB1) [25] and an increase in SINE efficacy in CLL cell lines (NALM-6) [24].